Astrazeneca on Track for Record High Close -- Data Talk
Astrazeneca PLC Sponsored ADR (AZN) is currently at $76.15, up $0.98 or 1.3% --Would be new all-time high (Based on available data back to May 12, 1993) --Would be the first record close since April
Dow JonesApr 29 09:55 ET
AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts
Yahoo FinanceApr 27 03:16 ET
Press Release: Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order Canada NewsWire HAMILTON, ON and BOSTON, April 25, 2024 HAMILTON, ON and BOSTON, Apr
Dow JonesApr 25 16:34 ET
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca Plc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $5 to $86,
MT NewswiresApr 25 12:55 ET
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Yahoo FinanceApr 25 08:00 ET
Trending Tickers: Microsoft, Google, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's
Yahoo FinanceApr 25 05:56 ET
Alphabet, Microsoft, Southwest Earnings: What to Watch
Yahoo FinanceApr 24 17:50 ET
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease
AstraZeneca (AZN.L, AZN.ST) said Tuesday the European Commission approved its Voydeya as an add-on medication for the treatment of the rare blood disease paroxysmal nocturnal hemoglobinuria.
MT NewswiresApr 23 02:28 ET
Astrazeneca (AZN) Could Be a Great Choice
Yahoo FinanceApr 18 11:45 ET
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD). Tezspire is a re
BenzingaApr 17 14:39 ET
Non-Hodgkin Lymphoma Therapeutics Market Size Is Set to Grow by USD 5.42 Billion From 2023-2027, AstraZeneca Plc, Baxter International Inc. and Bayer AG, and More to Emerge as Some of the Key Vendors, Technavio
The global non-hodgkin lymphoma therapeutics market size is estimated to grow by USD 5427.51 mn from 2023 to 2027, according to Technavio. The market ...
PR NewswireApr 16 17:25 ET
Express News | Deutsche Bank Upgrades AstraZeneca to Hold
Moomoo 24/7Apr 16 14:17 ET
AstraZeneca Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 — Deutsche Bank Upgrades Sell → Hold 02/12/2024 17.04% BMO Capital $82 → $80 Maintains Outperf
BenzingaApr 16 14:15 ET
Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer
New York, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company,
GlobeNewswireApr 16 13:00 ET
Express News | Asher Bio - Funding Round Had Participation From Existing Investors and Additional New Investors, Including AstraZeneca and Bristol Myers Squibb
Moomoo 24/7Apr 16 08:04 ET
Express News | Boehringer Says 2023 Group Sales 25.6 Billion Euros, up 9.7% at Constant Currencies
Moomoo 24/7Apr 16 04:30 ET
Express News | Boehringer Ingelheim Overtakes Bayer as Germany's Largest Drugmaker
Moomoo 24/7Apr 16 04:30 ET
Express News | Boehringer Reports Forex-Adjusted Gain in 2023 Pharmaceutical Division Sales of 10.3% to 20.8 Bln Euros
Moomoo 24/7Apr 16 04:30 ET
AstraZeneca Raised to Hold From Sell by Deutsche Bank
AstraZeneca Raised to Hold From Sell by Deutsche Bank
Dow JonesApr 16 03:38 ET
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial
Astrazeneca (AZN.L, AZN.ST) on Tuesday said Imfinzi combined with chemotherapy demonstrated a clinically meaningful long-term overall survival benefit in advanced biliary tract cancer patients during a phase 3 trial.
MT NewswiresApr 16 02:29 ET
No Data
No Data